FROM this month more women
with postmenopausal osteoporosis
will be able to receive
reimbursement for Prolia
(denosumab) following an
expanded listing on the
Pharmaceutical Benefit Scheme.
As such, Prolia (denosumab) is
now listed on the PBS as the sole
anti-resorptive agent for:
established postmenopausal
osteoporosis in a woman with
fracture due to minimal trauma;
and osteoporosis in women aged
70 years of age and older with a
Bone Mineral Density (BMD) Tscore
of -2.5 or less.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Aug 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.